Cell therapy company to expand in Devens
A new manufacturing plant will be built in Devens by Bristol Myers Squibb (BMS).
This plant will add to its cell therapy network where there are also facilities in Summit New Jersey and Bothell, Washington as well as several partners in Japan and Europe. Consequently, the company will be hiring several hundred people over the next few years, many of whom will require business card printing services, so that their commercial and clinical cell therapies can be produced.
The manufacturing plant is expected to span 244,000 square feet and will focus on the operations, development, and manufacturing of cell therapies. The company has recently received approval for its drug, Breyanzi, which will be manufactured commercially first. This drug provides chimeric antigen receptor T-cell therapy used to treat adults with large B-cell lymphoma. The drug is unique in that is made for each individual patient using their own T-cells, which after being extracted are genetically modified and readministered to the patient to kill the cells with lymphoma.
BMS then plans to explore and launch additional products related to cell therapy. The company believes that this strategy will hasten the career development for future employees, as well as current ones.
BMS is a global biopharmaceutical company with the goal to develop and deliver innovative treatments to help patients overcome serious diseases.
This plant will add to its cell therapy network where there are also facilities in Summit New Jersey and Bothell, Washington as well as several partners in Japan and Europe. Consequently, the company will be hiring several hundred people over the next few years, many of whom will require business card printing services, so that their commercial and clinical cell therapies can be produced.
The manufacturing plant is expected to span 244,000 square feet and will focus on the operations, development, and manufacturing of cell therapies. The company has recently received approval for its drug, Breyanzi, which will be manufactured commercially first. This drug provides chimeric antigen receptor T-cell therapy used to treat adults with large B-cell lymphoma. The drug is unique in that is made for each individual patient using their own T-cells, which after being extracted are genetically modified and readministered to the patient to kill the cells with lymphoma.
BMS then plans to explore and launch additional products related to cell therapy. The company believes that this strategy will hasten the career development for future employees, as well as current ones.
BMS is a global biopharmaceutical company with the goal to develop and deliver innovative treatments to help patients overcome serious diseases.